Search Videos by Topic or Participant
Browse by Series:

New Investigational Treatments in Prostate Cancer

Panelists: Raoul S. Concepcion, MD, Urology Associates, PC; Leonard G. Gomella, MD, Jefferson Kimmel; Lawrence I. Karsh, MD, Urology Center of Colorado;
Published: Wednesday, Jul 17, 2013
For High-Definition, Click
Two new antiandrogen agents are currently being explored as treatments for patients with prostate cancer, explains Evan Y. Yu, MD. The first is the agent orteronel (TAK-700), which is a nonsteroidal, selective CYP17 lyase inhibitor. This agent is similar to abiraterone acetate, notes Yu, but seems to have less hydroxylase activity. As a result, orteronel can be administered without a corticosteroid at lower doses. However, the two phase III trials exploring this agent are utilizing a higher dose along with the coadministration of prednisone.

The second interesting agent is ARN-509, explains Yu. This treatment is a fully antagonistic inhibitor of the androgen receptor and is similar to enzalutamide. However, Yu suggests, this agent offers a unique therapeutic index compared to enzalutamide. In early studies, ARN-509 penetrated the central nervous system less than enzalutamide, resulting in fewer seizures.


Slider Left
Slider Right
For High-Definition, Click
Two new antiandrogen agents are currently being explored as treatments for patients with prostate cancer, explains Evan Y. Yu, MD. The first is the agent orteronel (TAK-700), which is a nonsteroidal, selective CYP17 lyase inhibitor. This agent is similar to abiraterone acetate, notes Yu, but seems to have less hydroxylase activity. As a result, orteronel can be administered without a corticosteroid at lower doses. However, the two phase III trials exploring this agent are utilizing a higher dose along with the coadministration of prednisone.

The second interesting agent is ARN-509, explains Yu. This treatment is a fully antagonistic inhibitor of the androgen receptor and is similar to enzalutamide. However, Yu suggests, this agent offers a unique therapeutic index compared to enzalutamide. In early studies, ARN-509 penetrated the central nervous system less than enzalutamide, resulting in fewer seizures.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x